Clinical efficacy of combination therapy with ME3738 and pegylated interferon-alpha-2a in patients with hepatitis C virus genotype 1

Hepatology Research

Volumn 44, Issue 4, 2014, Pages 410-419

  Saibara, Toshiji ^a   Enomoto, Nobuyuki ^b   Kaneko, Shuichi ^c   Chayama, Kazuaki ^d   Sata, Michio ^e   Imawari, Michio ^f   Onishi, Saburo ^a   Okita, Kiwamu ^g  

^a KOCHI MEDICAL SCHOOL   (Japan)

^b UNIVERSITY OF YAMANASHI   (Japan)

^c KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^d HIROSHIMA UNIVERSITY   (Japan)

^e KURUME UNIVERSITY   (Japan)

^f Shin Yurigaoka General Hospital   (Japan)

^g Shimonoseki Kohsei Hospital   (Japan)

Author keywords

Clinical efficacy; Hepatitis C virus; ME3738; Pegylated interferon alpha 2a

Indexed keywords

ASPARTATE AMINOTRANSFERASE; HEMOGLOBIN; HYALURONIC ACID; IMMUNOGLOBULIN G; ME 3738; PEGINTERFERON ALPHA2A; SOYASAPOGENOL B; UNCLASSIFIED DRUG; VIRUS RNA;

ABNORMAL LABORATORY RESULT; ADULT; ALOPECIA; ARTHRALGIA; ARTICLE; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE COUNT; FEMALE; FEVER; FOLLOW UP; HEADACHE; HEMATOCRIT; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALAISE; MALE; MIDDLE AGED; MULTICENTER STUDY; NEUTROPHIL COUNT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RETINOPATHY; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE BLIND PROCEDURE; THROMBOCYTE COUNT; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD;

EID: 84898599422     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12139     Document Type: Article

References (14)

1. Kiyosawa K, Sodeyama T, Tanaka E etal. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990; 12 (4 Pt 1): 671-675.
2. Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology 1997; 26 (3 Suppl 1): 15S-20S.
3. McHutchison JG, Lawitz EJ, Shiffman ML etal.; The IDEAL Study Team. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580-583.
4. Manns MP, McHutchison JG, Gordon SC etal. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
5. Sezaki H, Suzuki F, Kawamura Y etal. Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads. Dig Dis Sci 2009; 54: 1317-1324.
6. Kuzuhara H, Nishiyama S, Minowa N etal. Protective effects of soyasapogenol A on liver injury mediated by immune response in a concanavalin A-induced hepatitis model. Eur J Pharmacol 2000; 391: 175-181.
7. Klein C, Wüstefeld T, Heinrich PC etal. ME3738 protects from concanavalin A-induced liver failure via an IL-6-dependent mechanism. Eur J Immunol 2003; 33: 2251-2261.
8. Hiasa Y, Kuzuhara H, Tokumoto Y etal. Hepatitis C virus replication is inhibited by 22β-methoxyolean-12-ene-3β, 24(4β)-diol (ME3738) through enhancing interferon-β. Hepatology 2008; 48: 59-69.
9. Abe H, Imamura M, Hiraga N etal. ME3738 enhances the effect of interferon and inhibits hepatitis C virus replication both in vitro and in vivo. J Hepatol 2011; 55: 11-18.
10. Saibara T, Sata M, Oonishi S, Okita K. Oral presentation session O-71, May 27, 2010, 46th Annual Meeting of Japan Society of Hepatology.
11. Koda M, Matunaga Y, Kawakami M, Kishimoto Y, Suou T, Murawaki Y. Fibroindex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C. Hepatology 2007; 45: 297-306.
12. Tanaka Y, Nishida N, Sugiyama M etal. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis. C. Nat Genet 2009; 41: 1105-1109.
13. Pegasys Subcutaneous Injection 180μg/90μg, Summary of Approval Application Dossier, Chugai Pharmaceutical Co., Ltd. October, 2003. PMDA website. Available at: http://www.info.pmda.go.jp/shinyaku/P200300026/index.html. Accessed September 5, 2010.
14. Ogasawara S, Akiba J, Nakayama M etal. Antiproliferative effect of ME3738, a derivative of soyasapogenol, on hepatocellular carcinoma cell lines in vitro and in vivo. Poster session 2 #854, November 6, 2011, 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD).